Immorna Biotherapeutics Reports the US FDA’s IND Clearance to Commence P-I/II Trial of JCXH-211 IV for Solid Tumors
Shots:
- The US FDA has cleared the IND application to commence the P-I/II dose-escalation and expansion trial of JCXH-211 (IV) for treating malignant solid tumors
- The P-I/II trial will investigate the safety, tolerability & RP2D of JCXH-211 combined with a checkpoint inhibitor (CPI) along with its effectiveness at RP2D
- JCXH-211, an LNP encapsulated srRNA coding for engineered human IL-12 protein, depicted the ability of tumor destruction in animal & patient-derived xenograft models compared to conventional mRNA candidates. Moreover, JCXH-211 (IT) alone showed promising safety, tolerability & anti-tumor activities such as abscopal effect in the P-I trial
Ref: PR Newswire | Image: Immorna Biotherapeutics
Related News: Medigene Receives Chinese Patent for MDG1015 to Treat Various Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
